A5073634181- Herpesvirus Infections and Treatments
- Animal Virus Infections Studies
- Malaria Research and Control
- SARS-CoV-2 and COVID-19 Research
- Mosquito-borne diseases and control
- Bartonella species infections research
- Acne and Rosacea Treatments and Effects
- Hepatitis B Virus Studies
- Poxvirus research and outbreaks
- Parasites and Host Interactions
- Hepatitis C virus research
- Ocular Diseases and Behçet’s Syndrome
- Vector-borne infectious diseases
- HIV Research and Treatment
- Cytomegalovirus and herpesvirus research
- Reproductive tract infections research
- Influenza Virus Research Studies
- Cancer, Stress, Anesthesia, and Immune Response
- Retinal and Optic Conditions
GlaxoSmithKline (United States)
2021-2025
National Institute of Allergy and Infectious Diseases
2021-2024
National Institutes of Health
2021-2024
Government of the United States of America
2024
Universities at Shady Grove
2021
Approximately 10 years after vaccination with the recombinant zoster vaccine (RZV), an interim analysis of this follow-up study ZOE-50/70 trials demonstrated that efficacy against herpes remained high. Moreover, safety profile clinically acceptable, suggesting clinical benefit RZV in ≥50-year-olds is sustained up to years.
The objective of the study was to assess safety and immunogenicity mRNA-1273 COVID-19 booster vaccination when co-administered with an egg-based standard dose seasonal quadrivalent influenza vaccine (QIV). This a phase 3, randomized, open-label study. Eligible adults aged ≥ 18 years were randomly assigned (1:1) receive (50 µg) QIV 2 weeks apart (Seq group) or concomitantly (Coad group). Primary objectives non-inferiority haemagglutinin inhibition (HI) anti-Spike protein antibody responses in...
Herpes zoster (HZ) results from reactivation of latent varicella-zoster virus. Adults at increased risk HZ (due to immunocompromising conditions or older age) are also pneumococcal disease, both which preventable by vaccination. We evaluated simultaneous versus sequential administration the adjuvanted recombinant vaccine (RZV) and 13-valent conjugate (PCV13) in adults aged ≥50 years.In this phase IIIB multinational trial (NCT03439657), participants were randomized 1:1 receive either first...
There is growing consensus that coronavirus disease 2019 booster vaccines may be coadministered with other age-appropriate vaccines. Adding to the limited available data supporting coadministration, especially adjuvanted vaccines, could enhance vaccine coverage in adults.In this phase 3, randomized, open-label study, eligible adults aged ≥50 years were randomly assigned (1:1) receive mRNA-1273 (50 µg) vaccination and a first dose of recombinant zoster (RZV1) 2 weeks apart (Seq group) or...
Background: Plasmodium falciparum (Pf) parasitemia during pregnancy causes maternal, fetal, and infant mortality. We conducted two trials in Ouélessébougou, Mali to optimize PfSPZ Vaccine dosage, schedule, antimalarial pre-treatment for future maternal immunizations.Methods: In MLSPZV3 trial (NCT03510481), we randomly assigned healthy 18-35-year-olds 3 doses of 9x105 (versus placebo) at 0,1,4-weeks or 0,8,16-weeks without pre-treatment, with 1-year booster dose. MLSPZV4 (NCT03989102),...
Abstract Background For the first time, we present data describing vaccine efficacy (VE), immunogenicity persistence and safety up to approximately 10 years after primary vaccination against HZ with RZV. We have previously shown that RZV demonstrated high VE in adults ≥ 50 of age (YOA) participating 2 phase 3 clinical trials (ZOE-50, NCT01165177 ZOE-70, NCT01165229), persisted year (Y) interim analysis extension study (ZOSTER-049, NCT02723773). Here describe for Y4 study. Understanding...
Abstract Background Patients with inflammatory bowel disease (IBD) are at higher risk of developing HZ compared to general population.1 The US Food and Drug Administration (FDA) approved RZV for adults ≥50 years age (YOA) in Oct 2017 ≥18 YOA who or will be increased due immunodeficiency immunosuppression, as patients IBD, Jul 2021. This study addresses an information gap vaccine effectiveness (VE) preventing among IBD YOA. Methods We conducted a retrospective matched cohort using the Optum...
<h3>Background:</h3> Patients with rheumatoid arthritis (RA) are at higher risk of herpes zoster (HZ) compared to the general population [1] due disease and associated therapy (particularly Janus kinase inhibitors [2]). The adjuvanted recombinant vaccine (RZV) demonstrated high efficacy in immunocompromised adults is approved for use HZ prevention by US Food Drug Administration (FDA) immunodeficient/immunosuppressed ≥18 years age (YOA) [3]. RZV also recommended Advisory Committee on...
ABSTRACT Background There is growing consensus that COVID-19 booster vaccines may be coadministered with other age-appropriate vaccines. Adding to the limited available data supporting coadministration, especially adjuvanted vaccines, could enhance vaccine coverage in adults. Methods In this phase 3, randomized, open-label study, eligible adults aged ≥50 years were randomly assigned (1:1) receive mRNA-1273 (50µg) vaccination and a first dose of recombinant zoster (RZV1) 2 weeks apart (Seq...
provide health authorities with useful information in real time to optimize the vaccination campaign.